Analysis Tools
behavior/neurological
|
• mice injected with tamoxifen at 14 months of age, but not at 3 months, take longer to walk through a balance beam
|
|
• mice injected with tamoxifen show worse rotarod performance; older mice injected with tamoxifen stay on the rod for a shorter time than younger mice injected with tamoxifen
|
|
• mice injected with tamoxifen exhibit abnormal gait which is most pronounced in mice that are injected at 14 months of age
|
|
• mice injected with tamoxifen exhibit a decrease in stride length
|
growth/size/body
|
• mice injected with tamoxifen for 5 days exhibit reduced body weight
• mice injected with tamoxifen at older ages (14 months) show earlier weight loss and lose more weight than those injected at younger ages (3 and 9 months)
|
mortality/aging
|
• some 14 month old mice die starting from 40 days after tamoxifen injection, however, none of the 3 month old mice die within 3 months after injection
|
nervous system
|
• mice injected with tamoxifen at 14 months of age show severe Purkinje neuron loss after 2 months of injection, while mice injected at 9 months show a modest level of degeneration, and mice injected at 3 months of age show largely intact Purkinje neurons
|
|
• dendritic branches are decreased in mice injected with tamoxifen at 14 months of age
|
|
• molecular layer thickness is decreased in mice injected with tamoxifen at 14 months of age
|
skeleton
|
• hunch-back appearance of 3, 9, and 14 month old mice is seen at 130, 75, and 50 days after tamoxifen injection
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| spinocerebellar ataxia type 17 | DOID:0050967 |
OMIM:607136 |
J:213011 | |
